Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBT (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed EBT for 16 consecutive years, with -$38.0 million as the latest value for Q4 2025.

  • For Q4 2025, EBT fell 59.39% year-over-year to -$38.0 million; the TTM value through Dec 2025 reached -$123.5 million, down 25.88%, while the annual FY2025 figure was -$123.5 million, 25.88% down from the prior year.
  • EBT hit -$38.0 million in Q4 2025 for Sangamo Therapeutics, down from -$35.1 million in the prior quarter.
  • Across five years, EBT topped out at $21.3 million in Q1 2023 and bottomed at -$120.8 million in Q2 2023.
  • Average EBT over 5 years is -$42.7 million, with a median of -$43.5 million recorded in 2022.
  • Year-over-year, EBT tumbled 3645.24% in 2021 and then surged 148.56% in 2023.
  • Sangamo Therapeutics' EBT stood at -$37.6 million in 2021, then plummeted by 37.67% to -$51.7 million in 2022, then decreased by 17.12% to -$60.6 million in 2023, then skyrocketed by 60.67% to -$23.8 million in 2024, then crashed by 59.39% to -$38.0 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$38.0 million, -$35.1 million, and -$20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.